Avalo Therapeutics expands leadership with CBO and SVP HR appointments

Avalo Therapeutics, Inc.

Taylor Boyd named Chief Business Officer; base salary $465k, target bonus 40%, 275k stock option inducement grant.
Ashley Ivanowicz appointed SVP, Human Resources; receives 100k stock option inducement grant.
Both options vest over 4 years with 12-month cliff; granted under Nasdaq inducement rule.
Company advancing AVTX-009 in Phase 2 LOTUS trial for hidradenitis suppurativa; data readout expected mid-2026.
Boyd previously led BD at Longboard, culminating in $2.6B acquisition by Lundbeck.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.